Mepolizumab (Nucala) Submission

Are you someone who suffers from chronic rhinosinusitis with nasal polyps (CRSwNP)? Or maybe you know someone who does.

The Therapeutic Goods Administration (TGA) has released for public consultation changes to the medication MEPOLIZUMAB, which is available in a 100 mg injection in 1 mL single-dose prefilled pen Nucala®. 

GlaxoSmithKline Australia Pty Ltd has put an application forward for a treatment of rhinosinusitis with nasal polyps to the TGA Pharmaceutical Benefits Advisory Committee (PBAC). This means if accepted, the medication for treating rhinosinusitis with nasal polyps would be listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised by the government. 

Have your say here: https://ohta-consultations.health.gov.au/ohta/online-comments-to-pbac-november-2022/

You may like to answer the following questions in your submission:

  • How has your daily life been impacted by CRSwNP? 
  • How do the symptoms affect you?
  • What’s the impact on work/education/family? 

You may also like to comment on the current management options for your CRSwNP. The closing date for submissions is 21 September 2022.

Acute Anaphylaxis CSS
Acute Anaphylaxis Clinical Care Standard - Learn more...
Atopic Dermatitis
allergy250K teens/young adults
Food allergy training

Our Supporters

Diamond


Viatris
Sanofi
Nestle
Allergy Concepts

Platinum


  • Bulla
  • NSW Food Authority
  • Novartis
  • Pfizer

Gold


  • dbv technologies
  • Mondelez
  • Nurticia
Silver

  • abbvie
  • Australian Camps Association
  • Bayer
  • Sanctuary Early Learning
  • Sweet William

© 2022 ALLERGY & ANAPHYLAXIS AUSTRALIA
ABN: 70 693 242 620

 


ALLERGY & ANAPHYLAXIS AUSTRALIA
is supported by funding from the
Australian Government,
Department of Health.


ALLERGY & ANAPHYLAXIS AUSTRALIA acknowledges and pays respect to the traditional custodians of the lands on which we work, live and play.

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.